181 related articles for article (PubMed ID: 30472492)
1. Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway.
Nogami A; Okada K; Ishida S; Akiyama H; Umezawa Y; Miura O
Transl Oncol; 2019 Feb; 12(2):336-349. PubMed ID: 30472492
[TBL] [Abstract][Full Text] [Related]
2. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.
Okada K; Nogami A; Ishida S; Akiyama H; Chen C; Umezawa Y; Miura O
Oncotarget; 2018 Feb; 9(10):8870-8886. PubMed ID: 29507660
[TBL] [Abstract][Full Text] [Related]
3. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
4. FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM.
Watanabe D; Nogami A; Okada K; Akiyama H; Umezawa Y; Miura O
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31756944
[TBL] [Abstract][Full Text] [Related]
5. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
[TBL] [Abstract][Full Text] [Related]
6. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
7. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
Akiyama H; Umezawa Y; Ishida S; Okada K; Nogami A; Miura O
Cancer Lett; 2019 Jul; 453():84-94. PubMed ID: 30946869
[TBL] [Abstract][Full Text] [Related]
8. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
9. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.
Green AS; Maciel TT; Hospital MA; Yin C; Mazed F; Townsend EC; Pilorge S; Lambert M; Paubelle E; Jacquel A; Zylbersztejn F; Decroocq J; Poulain L; Sujobert P; Jacque N; Adam K; So JC; Kosmider O; Auberger P; Hermine O; Weinstock DM; Lacombe C; Mayeux P; Vanasse GJ; Leung AY; Moura IC; Bouscary D; Tamburini J
Sci Adv; 2015 Sep; 1(8):e1500221. PubMed ID: 26601252
[TBL] [Abstract][Full Text] [Related]
10. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
11. Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication.
Scarpa M; Kapoor S; Tvedte ES; Doshi KA; Zou YS; Singh P; Lee JK; Chatterjee A; Ali MKM; Bromley RE; Hotopp JCD; Rassool FV; Baer MR
Oncotarget; 2021 Aug; 12(18):1763-1779. PubMed ID: 34504649
[TBL] [Abstract][Full Text] [Related]
12. A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia.
Czardybon W; Windak R; Gołas A; Gałęzowski M; Sabiniarz A; Dolata I; Salwińska M; Guzik P; Zawadzka M; Gabor-Worwa E; Winnik B; Żurawska M; Kolasińska E; Wincza E; Bugaj M; Danielewicz M; Majewska E; Mazan M; Dubin G; Noyszewska-Kania M; Jabłońska E; Szydłowski M; Sewastianik T; Puła B; Szumera-Ciećkiewicz A; Prochorec-Sobieszek M; Mądro E; Lech-Marańda E; Warzocha K; Tamburini J; Juszczyński P; Brzózka K
Oncotarget; 2018 Mar; 9(24):16917-16931. PubMed ID: 29682194
[TBL] [Abstract][Full Text] [Related]
13. PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
Scarpa M; Singh P; Bailey CM; Lee JK; Kapoor S; Lapidus RG; Niyongere S; Sangodkar J; Wang Y; Perrotti D; Narla G; Baer MR
Mol Cancer Ther; 2021 Apr; 20(4):676-690. PubMed ID: 33568357
[No Abstract] [Full Text] [Related]
14. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
Yoshida A; Ookura M; Zokumasu K; Ueda T
Biochem Pharmacol; 2014 Jul; 90(1):16-24. PubMed ID: 24735609
[TBL] [Abstract][Full Text] [Related]
15. The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors.
Qiu Y; Li Y; Chai M; Hua H; Wang R; Waxman S; Jing Y
Cell Death Discov; 2023 Feb; 9(1):44. PubMed ID: 36739272
[TBL] [Abstract][Full Text] [Related]
16. FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia.
Fang DD; Zhu H; Tang Q; Wang G; Min P; Wang Q; Li N; Yang D; Zhai Y
Transl Oncol; 2022 Jan; 15(1):101244. PubMed ID: 34710737
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
[TBL] [Abstract][Full Text] [Related]
18. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
19. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.
Nelson EA; Walker SR; Xiang M; Weisberg E; Bar-Natan M; Barrett R; Liu S; Kharbanda S; Christie AL; Nicolais M; Griffin JD; Stone RM; Kung AL; Frank DA
Genes Cancer; 2012 Jul; 3(7-8):503-11. PubMed ID: 23264850
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.
Katayama K; Noguchi K; Sugimoto Y
Oncotarget; 2018 Sep; 9(76):34240-34258. PubMed ID: 30344940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
